Min-che Chen

Title: Min-che Chen: Innovator in Antibody Fusion Proteins

Introduction

Min-che Chen is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of biotechnology, particularly in the development of antibody fusion proteins. With a total of four patents to his name, Chen's work focuses on innovative solutions for drug delivery and treatment of angiogenesis-related diseases.

Latest Patents

One of Chen's latest patents involves desmoglein 2 antibody fusion proteins for drug delivery. This invention relates to antibody fusion proteins that facilitate intra-cellular and intra-nucleus drug delivery. The fusion protein can be utilized as a peptide penetration system that specifically binds to various targets, enabling the delivery of effector peptides across biological barriers. Another notable patent includes DSG2-derived peptides, which are designed to inhibit epithelial-mesenchymal transition (EMT) and vasculogenic mimicry. This invention also provides pharmaceutical compositions that utilize these peptides for treating and preventing angiogenesis-related diseases.

Career Highlights

Throughout his career, Min-che Chen has worked with Asclepiumm Taiwan Co., Ltd, where he has contributed to various innovative projects. His expertise in biotechnology and drug delivery systems has positioned him as a key figure in his field.

Collaborations

Chen has collaborated with notable colleagues, including Ya-chuan Liu and Po-hao Chang, enhancing the impact of his research and inventions.

Conclusion

Min-che Chen's innovative work in antibody fusion proteins and drug delivery systems showcases his commitment to advancing biotechnology. His contributions have the potential to significantly impact the treatment of various diseases, making him a noteworthy inventor in the field.